Sanofi has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Sanofi’s portfolio of transformative therapies, which are marketed in countries around the world, represents ground-breaking and life-saving advances in medicine.
The site was purchased in 1982 and has since undergone construction of two large-scale manufacturing plants which were designed to international pharmaceutical standards. These plants manufacture Sevelamer Hydrochloride and Sevelamer Carbonate, which are the active ingredients in Renagel® and Renvela® respectively. Our continuous manufacturing process allows us to produce large volumes of our product.
The Haverhill site is also a testing, label and packaging centre for Secondary Operations for the company’s rare disease, transplant and oncology products including its treatments for the rate genetic disorders; Pompe Disease, Fabry Disease, Gaucher Disease and MPS1.